Skip to main content Back to Top
Advertisement

5/26/2016

Amoxicillin 875 mg Tablets

Products Affected - Description

    • Amoxicillin tablet, Ranbaxy, 875 mg, 20 count, NDC 63304-0763-20
    • Amoxicillin tablet, Ranbaxy, 875 mg, 100 count, NDC 63304-0763-01
    • Amoxicillin tablet, Ranbaxy, 875 mg, 500 count, NDC 63304-0763-05
    • Amoxicillin tablet, Sandoz, 875 mg, 20 count, NDC 00781-5061-20
    • Amoxicillin tablet, Sandoz, 875 mg, 100 count, NDC 00781-5061-01

Reason for the Shortage

    • Aurobindo had amoxicillin on shortage due to manufacturing delays.
    • Citron Pharma supplies product to current customers.
    • Ranbaxy has an FDA import ban on amoxicillin tablets.
    • Sandoz cannot provide a reason for the shortage.
    • West-Ward had amoxicillin on shortage due to increased demand.

Available Products

    • Amoxicillin tablet, Aurobindo, 875 mg, 100 count, NDC 65862-0015-01
    • Amoxicillin tablet, Citron Pharma, 875 mg, 100 count, NDC 57237-0029-01
    • Amoxicillin tablet, Teva, 875 mg, 100 count, NDC 00093-2264-01
    • Amoxicillin tablet, West-Ward, 875 mg, 20 count, NDC 00143-9951-01
    • Amoxicillin tablet, West-Ward, 875 mg, 100 count, NDC 00143-9951-20

Estimated Resupply Dates

    • Sandoz has amoxicillin 875 mg tablets on back order and the company cannot estimate a release date.
    • Ranbaxy has amoxicillin 875 mg tablets on long-term back order and the company cannot estimate a release date.
    • Several suppliers have product and are supplying the market.

Updated

Updated May 26, 2016 by Michelle Wheeler, PharmD, Drug Information Specialist. Created November 14, 2014 by Jane Chandramouli, PharmD, Drug Information Specialist. Copyright 2017, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins